Durable Biventricular Support Using Right Atrial Placement of the HeartWare HVAD

Patients with Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) levels 1–2 who either have or are at risk for right ventricular failure face significant morbidity and mortality after continuous flow left ventricular assist device (CF-LVAD) implantation. Currently, the op...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ASAIO journal (1992) 2018-05, Vol.64 (3), p.323-327
Hauptverfasser: Tran, Hao A, Pollema, Travis L, Silva Enciso, Jorge, Greenberg, Barry H, Barnard, Denise D, Adler, Eric D, Pretorius, Victor G
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 327
container_issue 3
container_start_page 323
container_title ASAIO journal (1992)
container_volume 64
creator Tran, Hao A
Pollema, Travis L
Silva Enciso, Jorge
Greenberg, Barry H
Barnard, Denise D
Adler, Eric D
Pretorius, Victor G
description Patients with Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) levels 1–2 who either have or are at risk for right ventricular failure face significant morbidity and mortality after continuous flow left ventricular assist device (CF-LVAD) implantation. Currently, the options for biventricular support are limited the Total Artificial Heart (TAH; CardioWest, Syncardia, Tuscon, AZ) or biventricular assist device (BiVAD), which uses bulky extracorporeal or implantable displacement pumps. We describe a successful series based on an innovative approach for biventricular support in consecutive INTERMACS levels 1–2 patients utilizing a HeartWare Ventricular Assist Device (HVAD; HeartWare, Framingham, MA) in a left ventricular (LV-HVAD) and a right atrial (RA-HVAD) configuration. From June 2014 through May 2016, 11 consecutive INTERMACS levels 1–2 patients with evidence of biventricular failure underwent implantation of a CF LVAD (10 LV-HVAD and 1 HeartMate II LVAD, Thoratec, Pleasanton, CA) and RA-HVAD pumps. A total of 4,314 BiVAD support days were accumulated in our case series. Seven patients have undergone orthotopic heart transplant, whereas 3 are ambulatory and are either waiting transplant or reconsideration for transplantation. There is one mortality in this case series, which was due to an intracranial bleed from supratherapeutic anticoagulation. Two other patients experienced hemorrhagic strokes, but without neurologic sequelae, whereas no patients have experienced ischemic strokes. There were two episodes of gastrointestinal bleeding. This is the largest series to date involving this approach with outcomes superior to those previously described in patients receiving biventricular support. We conclude this novel therapy is a viable alternative to current practices in the management of biventricular failure.
doi_str_mv 10.1097/MAT.0000000000000645
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1932850773</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1932850773</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4025-88dca4a3a02adfddb36a35ff264e32af2ae2182779dffc715100a9ba6d7faa593</originalsourceid><addsrcrecordid>eNp9kM1OwzAQhC0EoqXwBgj5yCXFP3HiHEMLFKkIBC1wi7aJ3QTcptgJFW-PUQtCHNjLrjTfzEqD0DElfUqS-OwmnfTJ74lCsYO6VHAZJCF_3vU3ETJgCY066MC5F0K8yOk-6jApQyok6aK7YWthZhQ-r97VsrFV3hqw-KFdrWrb4KmrlnN8X83LBqdeBYPvDORq4Vlca9yUCo8U2OYJrL8e0-Eh2tNgnDra7h6aXl5MBqNgfHt1PUjHQR4SJgIpixxC4EAYFLooZjwCLrRmUag4A81AMSpZHCeF1nlMBSUEkhlERawBRMJ76HSTu7L1W6tcky0qlytjYKnq1mU04UwKEsfco-EGzW3tnFU6W9lqAfYjoyT76jLzXWZ_u_S2k-2HdrZQxY_puzwPyA2wrk2jrHs17VrZrFRgmvL_7E_pWIAp</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1932850773</pqid></control><display><type>article</type><title>Durable Biventricular Support Using Right Atrial Placement of the HeartWare HVAD</title><source>Journals@Ovid LWW Legacy Archive</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Complete</source><creator>Tran, Hao A ; Pollema, Travis L ; Silva Enciso, Jorge ; Greenberg, Barry H ; Barnard, Denise D ; Adler, Eric D ; Pretorius, Victor G</creator><creatorcontrib>Tran, Hao A ; Pollema, Travis L ; Silva Enciso, Jorge ; Greenberg, Barry H ; Barnard, Denise D ; Adler, Eric D ; Pretorius, Victor G</creatorcontrib><description>Patients with Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) levels 1–2 who either have or are at risk for right ventricular failure face significant morbidity and mortality after continuous flow left ventricular assist device (CF-LVAD) implantation. Currently, the options for biventricular support are limited the Total Artificial Heart (TAH; CardioWest, Syncardia, Tuscon, AZ) or biventricular assist device (BiVAD), which uses bulky extracorporeal or implantable displacement pumps. We describe a successful series based on an innovative approach for biventricular support in consecutive INTERMACS levels 1–2 patients utilizing a HeartWare Ventricular Assist Device (HVAD; HeartWare, Framingham, MA) in a left ventricular (LV-HVAD) and a right atrial (RA-HVAD) configuration. From June 2014 through May 2016, 11 consecutive INTERMACS levels 1–2 patients with evidence of biventricular failure underwent implantation of a CF LVAD (10 LV-HVAD and 1 HeartMate II LVAD, Thoratec, Pleasanton, CA) and RA-HVAD pumps. A total of 4,314 BiVAD support days were accumulated in our case series. Seven patients have undergone orthotopic heart transplant, whereas 3 are ambulatory and are either waiting transplant or reconsideration for transplantation. There is one mortality in this case series, which was due to an intracranial bleed from supratherapeutic anticoagulation. Two other patients experienced hemorrhagic strokes, but without neurologic sequelae, whereas no patients have experienced ischemic strokes. There were two episodes of gastrointestinal bleeding. This is the largest series to date involving this approach with outcomes superior to those previously described in patients receiving biventricular support. We conclude this novel therapy is a viable alternative to current practices in the management of biventricular failure.</description><identifier>ISSN: 1058-2916</identifier><identifier>EISSN: 1538-943X</identifier><identifier>DOI: 10.1097/MAT.0000000000000645</identifier><identifier>PMID: 28841580</identifier><language>eng</language><publisher>United States: Copyright by the American Society for Artificial Internal Organs</publisher><ispartof>ASAIO journal (1992), 2018-05, Vol.64 (3), p.323-327</ispartof><rights>Copyright © 2018 by the American Society for Artificial Internal Organs</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4025-88dca4a3a02adfddb36a35ff264e32af2ae2182779dffc715100a9ba6d7faa593</citedby><cites>FETCH-LOGICAL-c4025-88dca4a3a02adfddb36a35ff264e32af2ae2182779dffc715100a9ba6d7faa593</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28841580$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tran, Hao A</creatorcontrib><creatorcontrib>Pollema, Travis L</creatorcontrib><creatorcontrib>Silva Enciso, Jorge</creatorcontrib><creatorcontrib>Greenberg, Barry H</creatorcontrib><creatorcontrib>Barnard, Denise D</creatorcontrib><creatorcontrib>Adler, Eric D</creatorcontrib><creatorcontrib>Pretorius, Victor G</creatorcontrib><title>Durable Biventricular Support Using Right Atrial Placement of the HeartWare HVAD</title><title>ASAIO journal (1992)</title><addtitle>ASAIO J</addtitle><description>Patients with Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) levels 1–2 who either have or are at risk for right ventricular failure face significant morbidity and mortality after continuous flow left ventricular assist device (CF-LVAD) implantation. Currently, the options for biventricular support are limited the Total Artificial Heart (TAH; CardioWest, Syncardia, Tuscon, AZ) or biventricular assist device (BiVAD), which uses bulky extracorporeal or implantable displacement pumps. We describe a successful series based on an innovative approach for biventricular support in consecutive INTERMACS levels 1–2 patients utilizing a HeartWare Ventricular Assist Device (HVAD; HeartWare, Framingham, MA) in a left ventricular (LV-HVAD) and a right atrial (RA-HVAD) configuration. From June 2014 through May 2016, 11 consecutive INTERMACS levels 1–2 patients with evidence of biventricular failure underwent implantation of a CF LVAD (10 LV-HVAD and 1 HeartMate II LVAD, Thoratec, Pleasanton, CA) and RA-HVAD pumps. A total of 4,314 BiVAD support days were accumulated in our case series. Seven patients have undergone orthotopic heart transplant, whereas 3 are ambulatory and are either waiting transplant or reconsideration for transplantation. There is one mortality in this case series, which was due to an intracranial bleed from supratherapeutic anticoagulation. Two other patients experienced hemorrhagic strokes, but without neurologic sequelae, whereas no patients have experienced ischemic strokes. There were two episodes of gastrointestinal bleeding. This is the largest series to date involving this approach with outcomes superior to those previously described in patients receiving biventricular support. We conclude this novel therapy is a viable alternative to current practices in the management of biventricular failure.</description><issn>1058-2916</issn><issn>1538-943X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kM1OwzAQhC0EoqXwBgj5yCXFP3HiHEMLFKkIBC1wi7aJ3QTcptgJFW-PUQtCHNjLrjTfzEqD0DElfUqS-OwmnfTJ74lCsYO6VHAZJCF_3vU3ETJgCY066MC5F0K8yOk-6jApQyok6aK7YWthZhQ-r97VsrFV3hqw-KFdrWrb4KmrlnN8X83LBqdeBYPvDORq4Vlca9yUCo8U2OYJrL8e0-Eh2tNgnDra7h6aXl5MBqNgfHt1PUjHQR4SJgIpixxC4EAYFLooZjwCLrRmUag4A81AMSpZHCeF1nlMBSUEkhlERawBRMJ76HSTu7L1W6tcky0qlytjYKnq1mU04UwKEsfco-EGzW3tnFU6W9lqAfYjoyT76jLzXWZ_u_S2k-2HdrZQxY_puzwPyA2wrk2jrHs17VrZrFRgmvL_7E_pWIAp</recordid><startdate>201805</startdate><enddate>201805</enddate><creator>Tran, Hao A</creator><creator>Pollema, Travis L</creator><creator>Silva Enciso, Jorge</creator><creator>Greenberg, Barry H</creator><creator>Barnard, Denise D</creator><creator>Adler, Eric D</creator><creator>Pretorius, Victor G</creator><general>Copyright by the American Society for Artificial Internal Organs</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201805</creationdate><title>Durable Biventricular Support Using Right Atrial Placement of the HeartWare HVAD</title><author>Tran, Hao A ; Pollema, Travis L ; Silva Enciso, Jorge ; Greenberg, Barry H ; Barnard, Denise D ; Adler, Eric D ; Pretorius, Victor G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4025-88dca4a3a02adfddb36a35ff264e32af2ae2182779dffc715100a9ba6d7faa593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tran, Hao A</creatorcontrib><creatorcontrib>Pollema, Travis L</creatorcontrib><creatorcontrib>Silva Enciso, Jorge</creatorcontrib><creatorcontrib>Greenberg, Barry H</creatorcontrib><creatorcontrib>Barnard, Denise D</creatorcontrib><creatorcontrib>Adler, Eric D</creatorcontrib><creatorcontrib>Pretorius, Victor G</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>ASAIO journal (1992)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tran, Hao A</au><au>Pollema, Travis L</au><au>Silva Enciso, Jorge</au><au>Greenberg, Barry H</au><au>Barnard, Denise D</au><au>Adler, Eric D</au><au>Pretorius, Victor G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Durable Biventricular Support Using Right Atrial Placement of the HeartWare HVAD</atitle><jtitle>ASAIO journal (1992)</jtitle><addtitle>ASAIO J</addtitle><date>2018-05</date><risdate>2018</risdate><volume>64</volume><issue>3</issue><spage>323</spage><epage>327</epage><pages>323-327</pages><issn>1058-2916</issn><eissn>1538-943X</eissn><abstract>Patients with Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) levels 1–2 who either have or are at risk for right ventricular failure face significant morbidity and mortality after continuous flow left ventricular assist device (CF-LVAD) implantation. Currently, the options for biventricular support are limited the Total Artificial Heart (TAH; CardioWest, Syncardia, Tuscon, AZ) or biventricular assist device (BiVAD), which uses bulky extracorporeal or implantable displacement pumps. We describe a successful series based on an innovative approach for biventricular support in consecutive INTERMACS levels 1–2 patients utilizing a HeartWare Ventricular Assist Device (HVAD; HeartWare, Framingham, MA) in a left ventricular (LV-HVAD) and a right atrial (RA-HVAD) configuration. From June 2014 through May 2016, 11 consecutive INTERMACS levels 1–2 patients with evidence of biventricular failure underwent implantation of a CF LVAD (10 LV-HVAD and 1 HeartMate II LVAD, Thoratec, Pleasanton, CA) and RA-HVAD pumps. A total of 4,314 BiVAD support days were accumulated in our case series. Seven patients have undergone orthotopic heart transplant, whereas 3 are ambulatory and are either waiting transplant or reconsideration for transplantation. There is one mortality in this case series, which was due to an intracranial bleed from supratherapeutic anticoagulation. Two other patients experienced hemorrhagic strokes, but without neurologic sequelae, whereas no patients have experienced ischemic strokes. There were two episodes of gastrointestinal bleeding. This is the largest series to date involving this approach with outcomes superior to those previously described in patients receiving biventricular support. We conclude this novel therapy is a viable alternative to current practices in the management of biventricular failure.</abstract><cop>United States</cop><pub>Copyright by the American Society for Artificial Internal Organs</pub><pmid>28841580</pmid><doi>10.1097/MAT.0000000000000645</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1058-2916
ispartof ASAIO journal (1992), 2018-05, Vol.64 (3), p.323-327
issn 1058-2916
1538-943X
language eng
recordid cdi_proquest_miscellaneous_1932850773
source Journals@Ovid LWW Legacy Archive; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Complete
title Durable Biventricular Support Using Right Atrial Placement of the HeartWare HVAD
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T00%3A35%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Durable%20Biventricular%20Support%20Using%20Right%20Atrial%20Placement%20of%20the%20HeartWare%20HVAD&rft.jtitle=ASAIO%20journal%20(1992)&rft.au=Tran,%20Hao%20A&rft.date=2018-05&rft.volume=64&rft.issue=3&rft.spage=323&rft.epage=327&rft.pages=323-327&rft.issn=1058-2916&rft.eissn=1538-943X&rft_id=info:doi/10.1097/MAT.0000000000000645&rft_dat=%3Cproquest_cross%3E1932850773%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1932850773&rft_id=info:pmid/28841580&rfr_iscdi=true